|(A;A)||2||2x increased prostate cancer risk|
|(A;G)||1.5||1.5x increased prostate cancer risk|
|(G;G)||1||Normal prostate cancer risk|
This SNP was also associated with hereditary-prostate-cancer (HPC) predisposition with an odds ratio of 1.97 (p=0.07) in a study of 116 affected Finnish families.[PMID 11941539]
See also:[PMID 20564318] Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population
[PMID 21221811] RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies
|CLNDBN||Prostate cancer, susceptibility to|
|CLNSRC||OMIM Allelic Variant|
[PMID 18566991] Joint effects of inflammation and androgen metabolism on prostate cancer severity.
[PMID 18575592] Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer.
[PMID 18676870] Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China.
[PMID 19379518] Development of a fingerprinting panel using medically relevant polymorphisms.
[PMID 19567509] Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.
[PMID 20565774] Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project.
|qualified_impact||Low clinical importance, Uncertain pathogenic|
|summary||Associated with increased risk of prostate cancer in individuals who already have a family history of prostate cancer, but studies have been unable to replicate this finding in sporadic (non-familial) prostate cancer cases.|
[PMID 27318894] Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.